TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7856899

Group type: EXPERIMENTAL
Intervention: Desflurane (1.25 MAC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoflurane (1.25 MAC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desflurane (100 micrograms/kg vecuronium)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoflurane (100 micrograms/kg vecuronium)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desflurane (reduction from 1.25 to 0.75 MAC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoflurane (reduction from 1.25 to 0.75 MAC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desflurane (reduction from 0.75 to 0.25 MAC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoflurane (reduction from 0.75 to 0.25 MAC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desflurane (90% response time)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoflurane (90% response time)
Number of subjects: 16
Study: 1940682

Group type: EXPERIMENTAL
Intervention: Lower cervical adjustments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-adjusted controls
Number of subjects: 0
Study: 6102915

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study: 31537702

Group type: EXPERIMENTAL
Intervention: Macrolide treatment
Number of subjects: 4898

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 4898
Study: 27811307

Group type: EXPERIMENTAL
Intervention: Stent retriever (Trevo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Merci device
Number of subjects: 0
Study: 25036870

Group type: EXPERIMENTAL
Intervention: 3.2% hypertonic saline (HTS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 74
Study: 25027478

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy for 8 weeks followed by Cognitive Behavioral Therapy for 8 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 21
Study: 22951349

Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System (EHCSS-K6)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Conventional cigarettes (CC)
Number of subjects: 316
Study: 19317065

Group type: EXPERIMENTAL
Intervention: Magnesium group (MgSO4 30 mg/kg in saline)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (saline without MgSO4)
Number of subjects: 30
Study: 17410461

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily (od)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (od)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily (od)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg twice daily (bid)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily (bid)
Number of subjects: 7
Study: 15626258

Group type: EXPERIMENTAL
Intervention: Cocaine flakes
Number of subjects: 220

Group type: COMPARATOR
Intervention: Tetracaine/adrenaline solution
Number of subjects: 220
Study: 11223706

Group type: EXPERIMENTAL
Intervention: CC + ethinyl estradiol (0.05 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CC + ethinyl estradiol (0.02 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 50
Study: 9849273

Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block (DPNB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Eutectic Mixture of Local Anesthetic (EMLA)
Number of subjects: 20
Study: 8014393

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) 3 x 10 IU in each nostril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2811377

Group type: EXPERIMENTAL
Intervention: Vaginal oestriol (E3) therapy at a dose of 0.5 mg per day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Vaginal oestradiol (E2) therapy at a dose of 0.05 mg per day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Untreated postmenopausal women
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Vaginal E3 therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Endometrium
Number of subjects: 29

Group type: COMPARATOR
Intervention: Endometrium vs Myometrium and Vagina
Number of subjects: 29

Group type: COMPARATOR
Intervention: Vagina and Uterus
Number of subjects: 29
Study: 875465

Group type: EXPERIMENTAL
Intervention: Bupicomide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 6
Study: 31438878

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) infusion for 72 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo infusion for 72 hours
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) as second line therapy in observational cohort
Number of subjects: 26

Group type: COMPARATOR
Intervention: No MgSO4 in observational cohort
Number of subjects: 26
Study: 28438473

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (15 mg/kg every 3 weeks)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Standard chemotherapy (paclitaxel 175 mg/m2 and carboplatin AUC 5)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 674

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 674
Study: 25940759

Group type: EXPERIMENTAL
Intervention: Gold Silk Sericin complex
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 40
Study: 23175723

Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator (tPA)
Number of subjects: 624

Group type: COMPARATOR
Intervention: No tPA
Number of subjects: 624
Study: 21937360

Group type: EXPERIMENTAL
Intervention: Rikkunshito
Number of subjects: 11
Study: 19377755

Group type: EXPERIMENTAL
Intervention: Cimetidine 35 mg/Kg/day (maximum 1200 mg/day) for three months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Zinc sulphate 10 mg/Kg/day (maximum 600 mg/day) for three months
Number of subjects: 18
Study: 17617271

Group type: EXPERIMENTAL
Intervention: TMC125 (200 mg) twice daily with darunavir-ritonavir and other antiretrovirals
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo with darunavir-ritonavir and other antiretrovirals
Number of subjects: 591
Study: 15302806

Group type: EXPERIMENTAL
Intervention: CRT on
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CRT off
Number of subjects: 14
Study: 11256874

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (0.625 mg/d, Premarin) and medroxyprogesterone acetate (5 mg/d, Farlutal)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 11907941

Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Estrogen plus any progestin
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Continuous progestin regimen in combination with estrogen
Number of subjects: 875

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study: 8041979

Group type: EXPERIMENTAL
Intervention: Clonidine (0.005 mg/kg/po)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lorazepam (0.03 mg/kg/po)
Number of subjects: 20
Study: 2466670

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 10
Study: 31758835

Group type: EXPERIMENTAL
Intervention: Topical latanoprost gel twice daily for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo with the same protocol
Number of subjects: 31
Study: 29890802

Group type: EXPERIMENTAL
Intervention: Squeezing and clapping manipulation, once a week for 3 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pelvic bandage immobilization, not less than 8 hours per day for 3 weeks
Number of subjects: 80
Study: 27898672

Group type: COMPARATOR
Intervention: Standard lifestyle advice alone (control group, n = 190)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Genetic risk estimate (n = 189)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Phenotypic risk estimate (n = 190)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Risk information (both genetic and phenotypic)
Number of subjects: 569
Study: 24909348

Group type: EXPERIMENTAL
Intervention: Supervised Training Curriculum (STC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Self-Directed Learning (SDL)
Number of subjects: 24
Study: 24450244

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 106
Study: 19924010

Group type: COMPARATOR
Intervention: CHO (6% carbohydrate supplement)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO/PRO H (4.5% carbohydrate plus 1.15% protein complex)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO/PRO L (3% carbohydrate plus 0.75% protein complex)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO, CHO/PRO H, CHO/PRO L
Number of subjects: 12
Study: 18392405

Group type: EXPERIMENTAL
Intervention: Beta-interferon
Number of subjects: 0
Study: 15897719

Group type: EXPERIMENTAL
Intervention: Kudzu extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12093949

Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula
Number of subjects: 195

Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 195
Study: 10494491

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.12% unoprostone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 40
Study: 8943601

Group type: EXPERIMENTAL
Intervention: Propofol and alfentanil
Number of subjects: 210

Group type: COMPARATOR
Intervention: Isoflurane and alfentanil
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study: 1826071

Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and triamterene
Number of subjects: 840

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Diuretics alone or diuretics plus methyldopa
Number of subjects: 840
Study: 7333741

Group type: EXPERIMENTAL
Intervention: Trial A (3 days L, 3 days H)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial B (3 days M, 3 days H)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trial C (6 days M)
Number of subjects: 0
Study: 30938760

Group type: EXPERIMENTAL
Intervention: Fructose (75 g)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Glucose (75 g)
Number of subjects: 37
Study: 28778213

Group type: EXPERIMENTAL
Intervention: Cued Recall
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reproduction
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Restudy
Number of subjects: 36
Study: 25751329

Group type: EXPERIMENTAL
Intervention: Half-dose group (methotrexate 0.15 mg/kg weekly)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 2-weekly group (methotrexate 0.3 mg/kg every 2 weeks)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (methotrexate stopped)
Number of subjects: 81
Study: 24176390

Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam (AZLI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22902212

Group type: EXPERIMENTAL
Intervention: Bevacizumab (intraocular injections every 6 weeks for 12 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham injections (first 6 months), then Bevacizumab (intraocular injections every 6 weeks for 6 months)
Number of subjects: 60
Study: 19397397

Group type: EXPERIMENTAL
Intervention: Direct Optical Access (DOA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Open Entry (Hasson)
Number of subjects: 202
Study: 17882731

Group type: EXPERIMENTAL
Intervention: Mebeverine hydrochloride film-forming gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Solcoseryl dental paste
Number of subjects: 0
Study: 15333608

Group type: EXPERIMENTAL
Intervention: High altitude (Protocol I)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Physical exercise (Protocol II)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of physical exercise and high altitude (Protocol III)
Number of subjects: 12
Study: 11821260

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 0
Study: 9475762

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for four years)
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study: 8553300

Group type: EXPERIMENTAL
Intervention: Twice daily inhaled budesonide (400 micrograms morning and bedtime)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Once daily inhaled budesonide (800 micrograms at bedtime)
Number of subjects: 40
Study: 2096340

Group type: EXPERIMENTAL
Intervention: Healon (1% sodium hyaluronate)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Viscoat (3% sodium hyaluronate and 4% chondroitin sulfate)
Number of subjects: 62
Study: 436626

Group type: EXPERIMENTAL
Intervention: 1.0 mg digoxin by mouth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 mg beta-acetyldigoxin by mouth
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1.0 mg digoxin intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally administered digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally administered beta-acetyldigoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenously administered digoxin
Number of subjects: 0
Study: 30644165

Group type: EXPERIMENTAL
Intervention: Cluster analysis of psychotic symptomatology
Number of subjects: 257
Study: 29976285

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg orally twice per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27569231

Group type: EXPERIMENTAL
Intervention: Parachute device implantation
Number of subjects: 31
Study: 23881608

Group type: EXPERIMENTAL
Intervention: Short-term strength training (ST) program, 2 days/week for 6 weeks, consisting of leg press, knee extension, and knee flexion exercises
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study: 22290521

Group type: EXPERIMENTAL
Intervention: Customized Power Balance performance mouth guard (PB MG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular over the counter boil-and-bite mouth guard (Reg MG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No mouth guard (No MG)
Number of subjects: 50
Study: 18678703

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 17916465

Group type: EXPERIMENTAL
Intervention: sipuleucel‐T (Provenge®, Dendreon)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other phase III studies
Number of subjects: 0
Study: 15030966

Group type: EXPERIMENTAL
Intervention: Standard amino acid solution (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Branched chain amino acid enriched solution (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study: 11474314

Group type: EXPERIMENTAL
Intervention: Amtolmetin‐guacyl (AMG) 1200 mg for 2 days and 600 mg for 12 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Piroxicam 40 mg for 2 days and 20 mg for 12 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AMG
Number of subjects: 42

Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 42
Study: 9502757

Group type: EXPERIMENTAL
Intervention: Digital luminescence mammography
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional film-screen mammography
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 22
Study: 8037393

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 19

Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 19
Study: 2522625

Group type: EXPERIMENTAL
Intervention: Plasma albumin (PM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placental albumin (PC)
Number of subjects: 80
Study: 30993452

Group type: EXPERIMENTAL
Intervention: FACIT-Pal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QLQ-C15-PAL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FACT-G7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FACIT-Pal-14
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FACT-G
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QLQ-C15-PAL Pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QLQ-C15-PAL Fatigue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FACIT-Pal PalCare
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FACIT-Pal TOI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FACT-G Physical Wellbeing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FACT-G Total
Number of subjects: 0
Study: 31779786

Group type: EXPERIMENTAL
Intervention: Staged nonculprit lesion PCI planned during the index hospitalization (median 1 day)
Number of subjects: 4041

Group type: EXPERIMENTAL
Intervention: Staged nonculprit lesion PCI planned after hospital discharge (median 23 days)
Number of subjects: 4041

Group type: COMPARATOR
Intervention: Intended nonculprit lesion PCI within 45 days
Number of subjects: 4041

Group type: COMPARATOR
Intervention: Intended nonculprit lesion PCI from 45 days to the end of follow-up
Number of subjects: 4041
Study: 29231475

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) at Neiguan (PC 6) and Zusanli (ST 36) for 4 weeks, 20 minutes twice a day.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional medication and nursing (Control group).
Number of subjects: 46
Study: 24219497

Group type: EXPERIMENTAL
Intervention: Autologous plasma rich in growth factors (P-PRP) added to deproteinized bovine bone matrix (DBBM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Deproteinized bovine bone matrix (DBBM)
Number of subjects: 15
Study: 23532005

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) calls
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: IVR calls with informal caregiver involvement
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: IVR calls with patients reporting fair or poor health
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: IVR system usability
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: IVR calls' impact on health management
Number of subjects: 268
Study: 21355447

Group type: EXPERIMENTAL
Intervention: Test formulation (levofloxacin 500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation (levofloxacin 500 mg)
Number of subjects: 12
Study: 18228523

Group type: EXPERIMENTAL
Intervention: PNL-2 staining
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HMB-45 staining
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Melan-A staining
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: S-100 staining
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MITF staining
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PNL-2 compared to Melan-A or MITF
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PNL-2
Number of subjects: 9
Study: 16472797

Group type: EXPERIMENTAL
Intervention: 40 mg/d oral fluvastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 80 mg/d oral fluvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine therapy (Control)
Number of subjects: 60
Study: 12901033

Group type: EXPERIMENTAL
Intervention: Pantoprazole suspension (20 mL of a suspension prepared from one crushed pantoprazole tablet and 840 mg of sodium bicarbonate solution)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pantoprazole tablet (one enteric-coated 40-mg pantoprazole tablet by mouth with 240 mL of water)
Number of subjects: 12
Study: 15945003

Group type: EXPERIMENTAL
Intervention: Pneumatic trabeculoplasty (PNT)
Number of subjects: 37
Study: 10863496

Group type: EXPERIMENTAL
Intervention: CARIOSTAT caries activity test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cultured microorganisms on MSB agar
Number of subjects: 0
Study: 8766515

Group type: EXPERIMENTAL
Intervention: Ambulation under epidural analgesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supine position under epidural analgesia
Number of subjects: 120
Study: 1835914

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7318439

Group type: EXPERIMENTAL
Intervention: 50 ug EE (+ 125ug d‐norgestrel)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 30 ug EE (+ 150ug d‐norgestrel)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chronic oral contraceptive users (110 participants)
Number of subjects: 13
Study: 31661976

Group type: EXPERIMENTAL
Intervention: AEO (0.25 g/kg feed)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: MOS (2 g/kg feed)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: PRO (0.15 g/kg feed)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: DEO (0.25 g/kg feed)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control (basal diet)
Number of subjects: 375
Study: 29065545

Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 25330083

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise at 80% of 1RM (HI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise at 20% of 1RM (LI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise at 20% of 1RM combined with partial blood flow restriction (LI + BFR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 24837597

Group type: EXPERIMENTAL
Intervention: Cisplatin/5-fluorouracil 100/1000 combined with panitumumab 9 mg/kg (Arm 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cisplatin/5-fluorouracil 100/1000 alone (Arm 2)
Number of subjects: 20